10-Q: 60P Q2 Loss Narrows, Research Revenue Soars Amid Capital Raises

60 Degrees Pharmaceuticals reports a significantly reduced net loss and surging research revenue in Q2 2025, driven by new contracts, despite a decline in product sales and ongoing 'going concern' doubts.

Summary

• Net loss attributed to 60 Degrees Pharmaceuticals, Inc. for Q2 2025 was $1,733,726, a significant reduction from $4,172,755 in Q2 2024.
• Net loss per common share improved to $(1.25) in Q2 2025 from $(21.12) in Q2 2024, influenced by a 1:5 reverse stock split on February 24, 2025.
• Product revenues decreased by 19.24% to $100,932 in Q2 2025 from $124,972 in Q2 2024, primarily due to a temporary shortage of Arakoda 16-ct boxes in the U.S. supply chain.
• Gross profit increased by 43.70% to $50,881 in Q2 2025 from $35,408 in Q2 2024, with gross margin improving to 50.41% from 28.33%.
• Research revenues surged by 28,325.69% to $206,939 in Q2 2025 from $728 in Q2 2024, driven by new contracts with USAMMDA ($116,948) and the University of Kentucky ($89,302).
• Total net revenue for Q2 2025 was $257,820, a substantial increase from $36,136 in Q2 2024.
• Research and Development (R&D) costs decreased by 91.93% to $249,884 in Q2 2025 from $3,095,326 in Q2 2024, mainly due to a non-cash charge of $2,625,000 in Q2 2024 related to stock issued to the University of Kentucky.
• General and Administrative (G&A) expenses increased by 42.78% to $1,612,764 in Q2 2025 from $1,129,560 in Q2 2024, due to higher sales, advertising, promotion, investor outreach, and stock-based compensation.
• Cash and cash equivalents increased to $1,966,930 as of June 30, 2025, from $1,659,353 as of December 31, 2024.
• Net cash used in operating activities increased to $3,047,494 for the six months ended June 30, 2025, compared to $2,328,650 for the same period in 2024.
• The company completed January 2025 and February 2025 offerings, raising net proceeds of approximately $804,346 and $908,627, respectively.
• A subsequent July 2025 offering generated approximately $4,459,874 in net proceeds, which management estimates will provide sufficient funds to remain viable through March 31, 2026.

Sentiment

Score: 4

Explanation: The sentiment is cautiously negative. While there are positives like reduced net loss, improved gross margin, and significant growth in research revenue, the persistent 'going concern' warning, continued reliance on capital raises, and a decline in core product sales due to supply issues indicate fundamental challenges and high financial risk. The recent capital raise provides a short-term runway but does not resolve the underlying profitability and operational sustainability concerns.

Positives

• Net loss significantly reduced in Q2 2025 to $1.73 million from $4.17 million in Q2 2024.
• Net loss per common share improved substantially to $(1.25) in Q2 2025 from $(21.12) in Q2 2024.
• Gross profit increased by 43.70% in Q2 2025, with gross margin improving to 50.41% from 28.33% due to lower per unit costs and reduced rebates.
• Research revenues saw an extraordinary increase of 28,325.69% in Q2 2025, driven by new contracts with USAMMDA and the University of Kentucky.
• Overall net revenue for Q2 2025 increased by 613.47% due to the surge in research revenues.
• European Arakoda sales volume increased by 293% in Q2 2025, attributed to growing interest in treating babesiosis.
• The company identified a total addressable market for Arakoda for babesiosis of up to $1.1 billion over the remaining 10-year patent life for the malaria indication.
• Introduction of a new 8-ct bottle format of Arakoda in the U.S. supply chain aims to reduce costs for short-term travelers and alleviate existing shortages.
• Cash and cash equivalents increased to $1,966,930 as of June 30, 2025, from $1,659,353 at December 31, 2024.
• Net cash provided by investing activities significantly improved to $1,650,834 for the six months ended June 30, 2025, from a net cash used of $140,373 in the prior year, primarily due to maturities of short-term investments.

Negatives

• Product revenues decreased by 19.24% in Q2 2025, primarily due to a temporary shortage of Arakoda 16-ct boxes in the U.S. supply chain.
• Domestic commercial product sales volume decreased by 17% in Q2 2025 compared to Q2 2024.
• Australian Kodatef sales volume declined by 3% quarter-over-quarter and 27% year-over-year.
• General and Administrative expenses increased significantly by 42.78% in Q2 2025, driven by higher sales, advertising, promotion, and investor outreach costs.
• Net cash used in operating activities increased to $3,047,494 for the six months ended June 30, 2025, indicating a higher cash burn from core operations.
• Total shareholders' equity decreased to $2,345,704 as of June 30, 2025, from $3,955,006 at December 31, 2024.
• Derivative liabilities increased to $776,172 as of June 30, 2025, from $640,830 at December 31, 2024, reflecting a loss on change in fair value.
• The company continues to operate at a net loss and has accumulated losses since inception, raising substantial doubt about its ability to continue as a going concern.
• The company remains dependent on raising additional capital to fund operations and achieve profitability, with no assurance of obtaining favorable terms or at all.
• Recent capital raises have resulted in significant dilution to existing stockholders, with further dilution expected from outstanding warrants.

Risks

• Substantial doubt about the company's ability to continue as a going concern for one year from the financial statement issuance date due to accumulated losses and inability to generate sufficient revenues to cover operating expenses.
• Dependence on raising additional capital through equity or debt financings, which may not be available on acceptable terms or at all, potentially leading to delays, limitations, reductions, or termination of product development and commercialization efforts.
• Potential for significant dilution to existing stockholders from the exercise of a substantial number of warrants issued in recent offerings (January 2025, February 2025, and July 2025), which could also negatively affect the common stock's market price.
• Material weaknesses in internal control over financial reporting, including a lack of full-time in-house personnel with technical knowledge for complex transactions, inadequate segregation of duties, and insufficient accounting staff for period-end financial disclosure and reporting.
• Reliance on a sole vendor for the supply of tafenoquine active pharmaceutical ingredient (API), which could lead to significant costs and efforts to rebuild the supply chain if the vendor ceases supply.
• Reliance on exclusive distributors in Australia and Europe; a failure to perform by any current distributor would disrupt patient access in those markets.
• Exposure to risks common in the biopharmaceutical industry, including challenges in developing product candidates, obtaining regulatory approval, achieving broad adoption by physicians and consumers, and significant competition.
• Economic uncertainties, including higher interest rates and potential financial institution insolvencies, could impact the company's ability to access cash, cash equivalents, and investments, or raise additional capital.

Future Outlook

Management estimates that the net proceeds of approximately $4.46 million from the July 2025 public offering will provide sufficient funds to remain viable through March 31, 2026, assuming no additional capital raises. The company expects to need additional capital to fund commercial support for its existing product and future clinical research trials and operating activities to achieve profitability, but there is no assurance of achieving or maintaining profitability. Future business demands may lead to higher cash utilization. The company plans to fund operations through third-party and related-party debt/advances, private placement of restricted securities, and subsequent stock offerings.

Management Comments

• "We are a specialty pharmaceutical company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases."
• "We have successfully achieved regulatory approval of Arakoda (Arakoda), a malaria preventative treatment that has been on the market since late 2019."
• "Based on current internal projections, taking into consideration the net proceeds of approximately $4.46 million received from the July 2025 public offering, we estimate that we will have sufficient funds to remain viable through March 31, 2026, assuming no additional capital raises."
• "We cannot give assurance that we can increase our cash balances or limit our cash consumption and thus maintain sufficient cash balances for our planned operations or future acquisitions."
• "However, we cannot assure you that we will be able to raise additional capital on acceptable terms, or at all."
• "As such, we have concluded that such plans do not alleviate the substantial doubt about our ability to continue as a going concern for one year from the date the accompanying financial statements are issued."

Industry Context

60 Degrees Pharmaceuticals operates in the highly competitive and evolving biopharmaceutical industry, specializing in infectious diseases. The company's focus on Arakoda (tafenoquine) for malaria prevention and its expansion into tick-borne diseases like babesiosis aligns with ongoing public health needs. The reported increase in European sales of Arakoda due to interest in babesiosis suggests a potential growth area within the broader infectious disease market, particularly as climate change and other factors may expand the geographic reach of vector-borne illnesses. The company's reliance on a single marketed product (Arakoda) and its need for continuous capital raises are common challenges for smaller biopharmaceutical firms in the development and commercialization phases.

Comparison to Industry Standards

• The company's accumulated losses and 'going concern' warning are not uncommon for early-stage biopharmaceutical companies focused on R&D and market penetration, but they highlight significant financial risk compared to established, profitable pharmaceutical firms.
• The reported potential addressable market of up to $1.1 billion for Arakoda in babesiosis, if realized, would represent a substantial opportunity, comparable to niche orphan drug markets or specific indications for established therapies.
• The significant increase in research revenues from government and academic contracts (USAMMDA, University of Kentucky) is a positive sign, indicating external validation and funding for its research pipeline, which is a common funding model in early-stage drug development.
• The high gross margin of 50.41% in Q2 2025 is favorable, suggesting efficient cost of goods sold for its product, which can be competitive within the specialty pharmaceutical sector, though overall profitability remains elusive due to high operating expenses.
• The company's reliance on exclusive distributors and a sole API vendor is a common practice for smaller biopharma companies but introduces supply chain and market access risks that larger, more diversified companies might mitigate through broader networks.

Corporate Governance

Related Party Transactions

• The company plans to fund operations through third-party and related-party debt/advances, in addition to other financing methods.

Stakeholder Impact

• Shareholders: Face significant dilution from recent and potential future equity offerings, and the value of their holdings is subject to the company's ability to achieve profitability and resolve going concern issues. The stock has undergone multiple reverse splits.
• Employees: The company's financial instability and 'going concern' warning could create uncertainty regarding job security and long-term prospects.
• Customers (resellers, distributors, patients): Experienced temporary shortages of Arakoda 16-ct boxes, which could impact product availability and patient access, though new packaging aims to mitigate this.
• Creditors: The SBA EIDL loan is collateralized by all tangible and intangible personal property, and the company has a contingent milestone payment obligation to Knight Therapeutics, Inc. upon certain events.
• Suppliers: The company's reliance on a sole vendor for tafenoquine API creates a single point of failure risk for its supply chain.

Next Steps

• Continue efforts to raise additional capital through third-party/related-party debt/advances, private placement of restricted securities, and subsequent stock offerings.
• Fund activities related to commercial support for the existing product, Arakoda.
• Fund future clinical research trials, particularly for the babesiosis indication.
• Address and resolve the material weaknesses in internal control over financial reporting, including hiring in-house personnel with technical knowledge, improving segregation of duties, and increasing accounting staff.
• Monitor and manage inventory levels, especially with the introduction of new Arakoda packaging formats.
• Continue to develop pipeline products containing tafenoquine, celgosivir, and botanical extracts from Australian Chestnut Trees.

Key Dates

Recommendation

While 60 Degrees Pharmaceuticals shows some positive operational trends, such as improved gross margin and a substantial increase in research revenue from new contracts, the persistent 'going concern' warning, continued reliance on dilutive capital raises, and recent decline in product sales due to supply issues present significant risks. The company's long-term viability hinges on achieving sustained profitability, which remains uncertain. For a seasoned investor, the current situation warrants a 'hold' position, acknowledging the speculative upside from pipeline development and market expansion (e.g., babesiosis) but emphasizing the high financial risk and the need for clear evidence of operational self-sufficiency before considering a 'buy'.

Keywords

Pharmaceuticals, Biotechnology, Infectious Diseases, Malaria, Babesiosis, Tafenoquine, ARAKODA, SEC Filing, 10-Q, Going Concern, Capital Raise, Clinical Trials, Drug Development, Biopharma